- Home
- UBFO vs IPHA Comparison
UBFO vs IPHA Comparison
Compare UBFO & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBFO
- IPHA
- Stock Information
- Founded
- UBFO 1987
- IPHA 1999
- Country
- UBFO United States
- IPHA France
- Employees
- UBFO N/A
- IPHA N/A
- Industry
- UBFO Major Banks
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- UBFO Finance
- IPHA Health Care
- Exchange
- UBFO Nasdaq
- IPHA Nasdaq
- Market Cap
- UBFO 162.0M
- IPHA 160.1M
- IPO Year
- UBFO N/A
- IPHA 2019
- Fundamental
- Price
- UBFO $8.35
- IPHA $1.83
- Analyst Decision
- UBFO
- IPHA Strong Buy
- Analyst Count
- UBFO 0
- IPHA 1
- Target Price
- UBFO N/A
- IPHA $11.00
- AVG Volume (30 Days)
- UBFO 22.1K
- IPHA 10.0K
- Earning Date
- UBFO 07-17-2025
- IPHA 03-27-2025
- Dividend Yield
- UBFO 5.70%
- IPHA N/A
- EPS Growth
- UBFO N/A
- IPHA N/A
- EPS
- UBFO 0.77
- IPHA N/A
- Revenue
- UBFO $47,362,000.00
- IPHA $20,831,349.00
- Revenue This Year
- UBFO N/A
- IPHA $209.83
- Revenue Next Year
- UBFO N/A
- IPHA $83.15
- P/E Ratio
- UBFO $10.80
- IPHA N/A
- Revenue Growth
- UBFO N/A
- IPHA N/A
- 52 Week Low
- UBFO $7.07
- IPHA $1.29
- 52 Week High
- UBFO $10.49
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- UBFO 44.46
- IPHA 33.33
- Support Level
- UBFO $8.04
- IPHA $1.82
- Resistance Level
- UBFO $8.74
- IPHA $2.21
- Average True Range (ATR)
- UBFO 0.23
- IPHA 0.07
- MACD
- UBFO -0.02
- IPHA -0.03
- Stochastic Oscillator
- UBFO 44.29
- IPHA 6.74
About UBFO United Security Bancshares
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.